Literature DB >> 10073949

Relationship of plasmin generation to cardiovascular disease risk factors in elderly men and women.

P A Sakkinen1, M Cushman, B M Psaty, B Rodriguez, R Boineau, L H Kuller, R P Tracy.   

Abstract

Plasmin-alpha2-antiplasmin complex (PAP) marks plasmin generation and fibrinolytic balance. We recently observed that elevated levels of PAP predict acute myocardial infarction in the elderly, yet little is known about the correlates of PAP. We measured PAP in 800 elderly subjects who were free of clinical cardiovascular disease in 2 cohort studies: the Cardiovascular Health Study and the Honolulu Heart Program. Median PAP levels did not differ between the Cardiovascular Health Study (6.05+/-1.46 nmol/L) and the Honolulu Heart Program (6.11+/-1.44 nmol/L), and correlates of PAP were similar in both cohorts. In CHS, PAP levels increased with age (r=0. 30), procoagulant factors (eg, factor VIIc, r=0.15), thrombin activity (prothrombin fragment F1+2, r=0.29), and inflammation-sensitive proteins (eg, fibrinogen, r=0.44; factor VIIIc, r=0.37). PAP was associated with increased atherosclerosis as measured by the ankle-arm index (AAI) (P for trend, </=0.001). PAP was negatively related to factors associated with the insulin resistance syndrome (IRS) (eg, fasting insulin, r=-0.26; body mass index, r=-0.26), possibly reflecting an association with plasminogen activator inhibitor-1 (r=-0.29). Although our study did not have sufficient power to detect a significant interaction, PAP and AAI appeared to be more weakly associated in subjects with more manifestations of the IRS: PAP appeared more strongly associated with AAI in the subgroup with 0 or 1 metabolic disorders (P</=0.001; slope estimate, -0.14) compared with the subgroup with 2 or more metabolic disorders (P=0.10; slope estimate, -0.08) and in those with non-insulin-dependent diabetes mellitus (P=0.46; slope estimate, -0.04). Although PAP reflects reactive fibrinolysis and is associated with subclinical atherosclerosis, this relationship may be weaker in populations with characteristics of the IRS, possibly reflecting the inhibitory effects of plasminogen activator inhibitor-1 on PAP. Decreased fibrinolysis in the presence of subclinical disease in subjects with hyperinsulinemia or glucose intolerance is consistent with the premise that depressed plasmin generation may enhance the progression of atherosclerosis in these people.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10073949     DOI: 10.1161/01.atv.19.3.499

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  19 in total

Review 1.  Candidate-based proteomics in the search for biomarkers of cardiovascular disease.

Authors:  Leigh Anderson
Journal:  J Physiol       Date:  2004-12-20       Impact factor: 5.182

2.  Associations of factor VIIIc, D-dimer, and plasmin-antiplasmin with incident cardiovascular disease and all-cause mortality.

Authors:  Aaron R Folsom; Joseph A C Delaney; Pamela L Lutsey; Neil A Zakai; Nancy S Jenny; Joseph F Polak; Mary Cushman
Journal:  Am J Hematol       Date:  2009-06       Impact factor: 10.047

3.  Associations between vitamin K status and haemostatic and inflammatory biomarkers in community-dwelling adults. The Multi-Ethnic Study of Atherosclerosis.

Authors:  M K Shea; M Cushman; S L Booth; G L Burke; H Chen; S B Kritchevsky
Journal:  Thromb Haemost       Date:  2014-05-22       Impact factor: 5.249

4.  Mechanisms of urokinase plasminogen activator (uPA)-mediated atherosclerosis: role of the uPA receptor and S100A8/A9 proteins.

Authors:  Stephen D Farris; Jie Hong Hu; Ranjini Krishnan; Isaac Emery; Talyn Chu; Liang Du; Michal Kremen; Helén L Dichek; Elizabeth Gold; Stephen A Ramsey; David A Dichek
Journal:  J Biol Chem       Date:  2011-05-02       Impact factor: 5.157

Review 5.  Biochemical markers of aging for longitudinal studies in humans.

Authors:  Peter M Engelfriet; Eugène H J M Jansen; H Susan J Picavet; Martijn E T Dollé
Journal:  Epidemiol Rev       Date:  2013-02-04       Impact factor: 6.222

6.  Plasminogen mediates the atherogenic effects of macrophage-expressed urokinase and accelerates atherosclerosis in apoE-knockout mice.

Authors:  Michal Kremen; Ranjini Krishnan; Isaac Emery; Jie Hong Hu; Katherine I Slezicki; Alyssa Wu; Kun Qian; Liang Du; Abigail Plawman; April Stempien-Otero; David A Dichek
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-28       Impact factor: 11.205

7.  Visceral obesity and hemostatic profile in patients with type 2 diabetes: the effect of gender and metabolic compensation.

Authors:  Elzbieta Kozek; Barbara Katra; Maciej Malecki; Jacek Sieradzki
Journal:  Rev Diabet Stud       Date:  2004-11-10

8.  Plasmin promotes foam cell formation by increasing macrophage catabolism of aggregated low-density lipoprotein.

Authors:  Abigail S Haka; Inna Grosheva; Rajesh K Singh; Frederick R Maxfield
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-05-23       Impact factor: 8.311

Review 9.  The hemostasis system in murine atherosclerosis.

Authors:  Takayuki Iwaki; Victoria A Ploplis; Francis J Castellino
Journal:  Curr Drug Targets       Date:  2008-03       Impact factor: 3.465

10.  Macrophage gene expression and foam cell formation are regulated by plasminogen.

Authors:  Riku Das; Swetha Ganapathy; Ganapati H Mahabeleshwar; Carla Drumm; Maria Febbraio; Mukesh K Jain; Edward F Plow
Journal:  Circulation       Date:  2013-02-11       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.